StockData
Entera Bio Ltd. logo

Entera Bio Ltd. (ENTX) stock

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$3.00−0.02 (-0.66%)

Close on Nov 17, 2026Market cap $519.43MP/E –Yield –

Entera Bio price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Entera Bio's price to sales ratio was 393.1× on Jul 31, 2025, against 92.8× a year earlier. Over the last 5 years it ranged from 49.0× to 465.6×, with a median of 128.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 2025393.1×+46.9
2023Jul 31, 2023346.2×+272.4
2022Dec 30, 202273.8×−144.4
2021Dec 31, 2021218.2×+134.7
2020Dec 31, 202083.4×+34.4
2019Dec 31, 201949.0×–

More Entera Bio figures

See a number that looks wrong?